Revised ceiling price secured through NPPA Review Committee. Price revision reflected updated input cost architecture, exchange rate movement, and documented market dynamics. The corresponding NPPA Office Order was issued with effect across all market formulations covered.
Restored commercial viability for a formulation category that had been operating at margins below production economics. Preserved continued market availability and prevented product exit from the Indian market, which would have compressed patient access in a therapeutic area with limited alternatives.